Chemists and pharmaceutical science experts Jeroen Kool, Rob Leurs and Henry Vischer from the Amsterdam Institute of Molecular and Life Sciences (AIMMS) are collaborating within the Biodiversity2Drugs-consortium on the project titled “Nature-based solutions for biodiversity, human well-being, and transformative change.”
Biodiversity2Drugs project
Biodiversity2Drugs is a large international collaboration, coordinated by chemist and molecular biologist Christian Gruber from the Institute of Pharmacology at the Medical University of Vienna. The project aims to discover bioactive peptides from diverse natural sources—including venomous snakes, insects, spiders, marine organisms, and plants—for biochemical studies and therapeutic applications. By employing evolution- and ecology-driven sample collection, innovative bioinformatics (including AI and machine learning tools), environmentally friendly chemistry, and high-throughput pharmacological screening, the researchers aim to develop nature-based drugs that are both effective and sustainable. These drugs have potential applications in treating major health issues such as chronic pain, autoimmune diseases, and other conditions.
Sustainable drug discovery and development
The societal impact of Biodiversity2Drugs lies in promoting sustainable drug discovery and development from natural sources. The project highlights the pharmacological potential of these peptides, advocates for environmental protection and biodiversity conservation, and communicates its achievements to the public, policymakers, and industry stakeholders.
Interdisciplinary collaboration
The collaboration involves partners from 18 countries, creating a diverse pool of expertise that includes biologists, ecologists, bioinformaticians, structural biologists, chemists, and pharmacologists. This international approach maximizes resources and innovation while respecting biodiversity by responsibly collecting samples. Building on previous collaborations, the project ensures that knowledge and methodologies are shared globally to better address biodiversity loss and health challenges.
Excellence in biodiversity research
Biodiversity2Drugs operates under the Biodiversa+ European Biodiversity Partnership, which supports high-quality biodiversity research with tangible impacts on policy and society. This consortium was jointly developed by BiodivERsA and the European Commission as part of the EU Biodiversity Strategy 2030. The initiative contributes to the goal of “restoring nature in Europe by 2030 and ensuring that by 2050, people live in harmony with nature.”
